| Literature DB >> 29320401 |
Karina Sanches Machado d'Almeida1,2, Stefanny Ronchi Spillere3,4, Priccila Zuchinali5, Gabriela Corrêa Souza6,7,8,9.
Abstract
BACKGROUND: Heart failure (HF) is a complex syndrome and is recognized as the ultimate pathway of cardiovascular disease (CVD). Studies using nutritional strategies based on dietary patterns have proved to be effective for the prevention and treatment of CVD. Although there are studies that support the protective effect of these diets, their effects on the prevention of HF are not clear yet.Entities:
Keywords: DASH; dietary patterns; heart failure; mediterranean diet
Mesh:
Year: 2018 PMID: 29320401 PMCID: PMC5793286 DOI: 10.3390/nu10010058
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Characteristics of studies.
| Study | SD | Condition or Cohort Name | Age | Intervention | Control | Duration of Intervention | Outcome | |
|---|---|---|---|---|---|---|---|---|
| Tuttle et al., 2008 [ | RCT | Patients after a first myocardial infarction | 201 | Mediterranean diet: 58 ± 10 | Mediterranean diet | Usual diet | 2 years | |
| Papadaki et al., 2017 [ | RCT | High risk of cardiovascular disease | 7403 | TMD + VOO: 67.0 ± 6.2 | TMD + VOO | Low-fat | 4.8 years | |
| Fitó et al., 2014 [ | RCT | High risk of cardiovascular disease | 930 | TMD + VOO: 66.4 ± 5.7 | TMD + VOO | Low-fat | 1 year | |
| Lorgeril et al., 1999 [ | RCT | Patients after a first myocardial infarction | 423 | NR | Mediterranean diet | Prudent Western-type diet | 4 years | |
| Wirth et al., 2016 [ | Cohort | European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam | 24,008 | 35 to 65 | Mediterranean diet | NA | 8.2 years | |
| Chrysohoou et al., 2010 [ | Cohort | Patients after an acute coronary event | 1000 | EF < 40%: Male: 64 ± 14 | Mediterranean diet | NA | 2 years | |
| Tektonidis et al., 2015 [ | Cohort | Swedish mammography cohort | 32,921 | 48 to 83 | Mediterranean diet | NA | 10 years | |
| Tektonidis et al., 2016 [ | Cohort | Cohort of Swedish men | 37,308 | 45 to79 | Mediterranean diet | NA | 11 years | |
| Del Gobbo et al., 2015 [ | Cohort | Cardiovascular health study of elderly patients with and without CVD | 4490 | Q1: 72.2 ± 5.3 | DASH | NA | 21 years | |
| Levitan et al., 2009a [ | Cohort | Swedish mammography cohort | 36,019 | 48–83 | DASH | NA | 7 years | |
| Levitan et al., 2009b [ | Cohort | Cohort of Swedish men | 38,987 | 45 to 79 | DASH | NA | 9 years | |
| Nguyen et al., 2012 [ | Cross-sectional | Multi-ethnic group free of clinical cardiovascular disease (CVD) | 4506 | 45 to 84 | DASH | NA | NA | |
| Andersson et al., 2016 [ | RTC | Healthy postmenopausal women | 68 | NR | Paleolithic diet (30% PTN, 40% LIP, 30% CHO) | Nordic nutrition recommendation (15% PTN, 25–30% LIP, 55–60% CHO) | 2 years | |
| Pai et al., 2015 [ | Cross-sectional | Adventist health study-2 | 206 | 74.0 ± 10.0 | Vegetarian diet | non-vegetarian diet | NA | LV diastolic dysfunction: OR 0.42 (IC 95% 0.24–0.73) |
ACS: Acute coronary syndrome; AMI: acute myocardial infarction; BNP: Brain-Type Natriuretic Peptide; CHO: carbohydrate; CVD: cardiovascular disease; DASH: dietary approaches to stop hypertension; DM: diabetes mellitus; EF: Ejection fraction; HF: Heart failure; LIP: lipids; HR: hazard ratio; LV: left ventricle; LVEF: ejection fraction of the left ventricle; NA: not applicable; NR: not reported; NT: N-terminal; PTN: protein; RCT: randomized clinical trial; RR: relative risk; SD: study design; TMD+VOO: Traditional Mediterranean diet + olive oil. 1 (sex, age, schooling, body mass index (BMI), smoking, HDL: high density lipoprotein, LDL: low density lipoprotein, diabetes mellitus, systolic blood pressure, use of diabetes medications, use of blood pressure lowering medications, alcohol intake and physical activity); OR: odds ratio; RR: relative risk. 2 (model 1 + energy consumption). 3 (model 2 + race/ethnicity).
Figure 1Flowchart for selection of articles.
Quality assessment of studies.
| Study | SD | RSG | AC | Blinding of Research | Blinding of PP | Blinding of OA | LE | Do They Describe Confounders in an Adjusted Analysis? | Do You Assess the Balance Between the Groups at the Start of the Study? |
|---|---|---|---|---|---|---|---|---|---|
| Andersson et al. | RCT | High risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | NA | NA |
| Fitó et al. | RCT | Low risk | Low risk | Unclear risk | Unclear risk | Low risk | Low risk | NA | NA |
| Lorgeril et al. | RCT | Unclear risk | Unclear risk | Unclear risk | Unclear risk | Low risk | Low risk | NA | NA |
| Papadaki et al. | RCT | Low risk | Low risk | Unclear risk | Unclear risk | Low risk | Low risk | NA | NA |
| Tuttle et al. | RCT | Low risk | Low risk | Unclear risk | Unclear risk | Low risk | Low risk | NA | NA |
| Chrysohoou et al. | RCT | Low risk | Low risk | Unclear risk | Unclear risk | Low risk | Low risk | NA | NA |
| Del Gobbo et al. | Cohort | NA | NA | NA | NA | NA | NA | Low risk | High risk |
| Levitan et al. | Cohort | NA | NA | NA | NA | NA | NA | Low risk | Low risk |
| Levitan et al. | Cohort | NA | NA | NA | NA | NA | NA | Low risk | Low risk |
| Tekitonidis et al. | Cohort | NA | NA | NA | NA | NA | NA | Low risk | Low risk |
| Tekitonidis et al. | Cohort | NA | NA | NA | NA | NA | NA | Low risk | Low risk |
| Wirth et al. | Cohort | NA | NA | NA | NA | NA | NA | Low risk | Low risk |
| Nguyen et al. | Cross-sectional study | NA | NA | NA | NA | NA | NA | Low risk | Low risk |
| Pai et al. * | Cross-sectional study | NA | NA | NA | NA | NA | NA | Low risk | High risk |
AC: allocation concealment; LE: losses and exclusions; NA: not applicable; OA: outcome assessment; PP: participants and personnel; RCT: randomized clinical trial; RSG: random sequence generation; SD: study design; (*) abstract.